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High-dose intravenous melphalan with autologous stem cell AL amyloidosis is a systemic disease characterized by
transplantation in AL amyloidosis-associated end-stage renal progressive organ dysfunction resulting from the tissue
disease. deposition of monoclonal immunoglobulin light chainsBackground. The development of end-stage renal disease
or light-chain fragments in the form of amyloid fibrils.(ESRD) is common among patients with amyloid light-chain
The kidney is one of the most common sites of amyloidAL amyloidosis-associated renal disease and survival of these
patients is poor. High-dose intravenous melphalan and autolo- deposition, with clinically evident renal involvement oc-
gous stem cell transplantation induce remission of the plasma curring in 48% to 82% of patients [1–5]. Most patients
cell dyscrasia in a significant proportion of patients with AL with AL amyloidosis-associated renal disease have ne-
amyloidosis. The efficacy and tolerability of such treatment for
phrotic syndrome, often with massive proteinuria andpatients with AL amyloidosis-associated ESRD are unknown.
refractory edema [6]. Renal insufficiency without pro-Methods. Between June 1994 and June 2000, 15 patients
with AL amyloidosis-associated ESRD were treated with intra- teinuria occurs in a subset of patients with isolated tubu-
venous melphalan (70 to 200 mg/m2) and autologous peripheral lointerstitial amyloid deposition. The natural history of
blood stem cell transplantation. Clinical and laboratory data amyloidosis-associated renal disease is progressive loss
were prospectively collected prior to treatment, during the
of glomerular filtration rate (GFR) [1, 7]. In a series ofperitransplant period, and at 3 months, 12 months, and annually
211 patients with AL amyloidosis, one third of thosethereafter. Treatment outcomes and toxicities were compared
with renal disease at presentation progressed to dialysiswith 180 non-ESRD patients treated during the study period.
Results. Eight of 15 patients (53%) had a hematologic com- dependence [4]. The median time from presentation to
plete response following treatment. Two patients (13%) died initiation of dialysis in these patients was 13.8 months
during the peritransplant period. Transfusion requirements and median survival from the onset of dialysis was 8were greater and there was a trend toward increased severity
months [4].of mucositis in the ESRD patients compared with the non-
Cyclic oral melphalan and prednisone has been consid-ESRD patients. Median survival for the ESRD patients with
a hematologic complete response was 4.5 years. Five patients ered the standard treatment for AL amyloidosis. How-
with hematologic complete response have either undergone or ever, the response to this treatment is unsatisfactory with
are awaiting renal transplantation. a median survival of only 16 to 18 months and rare erad-
Conclusion. High-dose intravenous melphalan with stem
ication of the plasma cell dyscrasia [3, 5]. At this institu-cell transplantation is an effective treatment in selected patients
tion, we have used high-dose intravenous melphalan withwith AL amyloidosis-associated ESRD. Although the toxicity
profile is greater in ESRD patients, the treatment offers the autologous peripheral blood stem cell transplantation
possibility of successful renal transplantation if hematologic (HDM/SCT) since 1994 as a more aggressive treatment
remission is achieved. This treatment should be considered for approach for selected patients with AL amyloidosis. The
patients with AL amyloidosis-associated ESRD.
goal of this treatment is to eliminate the clonal plasma
cells producing the amyloidogenic light chains. This treat-
ment has resulted in a hematologic complete response,Key words: AL amyloidosis, renal failure, treatment, autologous stem
cell transplantation, end-stage renal disease, melphalan. defined as normal bone marrow biopsy and absence of
serum and urine monoclonal protein, in 40% to 50% ofReceived for publication June 13, 2002
patients, a 4-year survival rate of 60%, and clinical im-and in revised form September 2, 2002
Accepted for publication October 11, 2002 provement in a substantial proportion of surviving pa-
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proteinuria, 71% of those with a hematologic complete or arrhythmias resistant to medical management, and
response ultimately had a marked reduction in protein- persistent symptomatic pleural effusions. During the study
uria [11]. However, because of the toxicity associated period, 42% of all patients evaluated both met eligibility
with such treatment there has been concern about its criteria and elected to undergo treatment with HDM/
utility in patients with end-stage renal disease (ESRD). SCT. Fifteen of 25 patients with ESRD (60%) evaluated
Other centers have suggested that renal failure is a pre- during this period underwent treatment with HDM/SCT.
dictor of poor clinical response to chemotherapy [12],
and it has been proposed that AL amyloidosis patients Treatment
with renal insufficiency are not ideal candidates for mye- Peripheral blood stem cells were mobilized using gran-
loablative chemotherapy regimens because of high mor- ular-colony stimulating factor (G-CSF) (Filgrastim; Am-
bidity and mortality rates [13]. The objective of the pres- gen, Inc., Thousand Oaks, CA, USA), 10 to 16 g/kg, as
ent study was to investigate the outcomes of HDM/SCT the sole mobilizing agent or in combination with granular
among patients with AL amyloidosis-associated ESRD. macrophage-colony stimulating factor (GM-CSF) (Sar-
gamostim, Immunex, Seattle, WA, USA), 250 g/m2, as
METHODS previously described [8, 9]. Melphalan was administered
intravenously in divided doses during 2 consecutive days.Patients
The total dose of melphalan ranged from 70 to 200 mg/m2,Approval for the study was obtained from the Institu-
depending on patient’s age, severity of cardiac disease,tional Review Board of Boston University Medical Cen-
and performance status. Stem cells were infused 24 toter. All patients with AL amyloidosis-associated ESRD
72 hours after melphalan administration. Hemodialysistreated with HDM/SCT at Boston University Medical
patients were dialyzed according to the patient’s usualCenter between July 1994 and June 2000 were included
schedule but with an interval of at least 2 hours betweenin this analysis. Requirements for the diagnosis of AL
either the administration of melphalan or infusion ofamyloidosis included demonstration of tissue amyloid de-
stem cells and the initiation of hemodialysis. Peritonealposits by Congo Red staining, presence of monoclonal
dialysis exchanges were performed according to the pa-immunoglobulin protein by serum or urine immunofixa-
tient’s usual schedule. Antimicrobial prophylaxis with antion electrophoresis, and evidence of clonal plasmacy-
oral quinolone and oral acyclovir was started 1 day aftertosis by bone marrow biopsy.
stem cell infusion and continued until neutrophil en-Organ involvement was assessed by a multidisciplinary
graftment. A neutrophil count 500/L for 2 days andteam that included subspecialists in rheumatology, he-
matology, nephrology, cardiology, pulmonary, gastro- platelet count20,000/L for 2 days without transfusion
enterology, and neurology. Patients were considered to in the preceding 48 hours constituted neutrophil and plate-
have AL amyloidosis-associated ESRD if they were dial- let engraftment, respectively. Toxicities were recorded
ysis-dependent prior to HDM/SCT, and if renal failure and graded according to National Cancer Institute com-
was attributed to amyloidosis based on clinical or histo- mon toxicity criteria. Treatment was performed in the
logic findings. Cardiac involvement was defined by septal outpatient setting with hospitalization only if needed for
or posterior wall thickening 12 mm by echocardiogra- treatment- or disease-related complications.
phy in the absence of a history of hypertension or under-
lying cardiac disease, or by amyloid-related congestive Evaluations
heart failure or arrythmia. Hepatic involvement required Patients were evaluated prior to treatment, at 3 and
the presence of hepatomegaly 4 cm below the right 12 months following treatment, and annually thereafter.
costal margin at the midclavicular line by physical exami-
At each evaluation, the status of the plasma cell dyscrasia
nation or serum alkaline phosphatase level 2 times the
was determined by bone marrow biopsy and immunofix-upper limit of normal values. Neurologic involvement
ation electrophoresis of serum (SIFE) and urine (UIFE).was defined as a decrease in systolic blood pressure 20
Hematologic complete response required the absence ofmm Hg with upright posture, gastric atony by gastric
detectable monoclonal protein by SIFE and UIFE, asemptying scan, symptoms of early satiety, or symptoms
well as bone marrow biopsy with 5% plasma cells andor physical examination findings of peripheral neuropa-
no light-chain predominance. Survival was recorded fromthy. Performance status was assessed by two or more
the time of treatment, beginning with the first dose ofclinicians according to the Southwest Oncology Group
recombinant growth factor for stem cell mobilization.(SWOG) criteria [14].
Treatment-related toxicities and blood product require-Exclusion criteria for HDM/SCT included left ventric-
ments were tracked prospectively. The peritransplantular ejection fraction 40%, supine systolic blood pres-
period was defined as 90 days from the initiation ofsure90 mm Hg, oxygen saturation 95% on room air,
SWOG performance status 3, congestive heart failure growth factor administration for stem cell mobilization.
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Table 1. Baseline characteristics and organ involvement of end-stage renal disease (ESRD) patients
Disease Monoclonal Dialysis SWOG Predominant
durationa light-chain duration Dialysis performance organ Affected Cardiac
Patient Age/sex months isotype months modality statusb involvement organsc involvement
1 61/M 24 Lambda 7 PD 1 Kidney 2 
2 43/M 30 Lambda 7 PD 1 Kidney 1
3 47/M 19 Lambda 3 PD 2 Kidney 2 
4 43/F 9 Kappa 7 HD 1 Kidney 1
5 61/M 11 Lambda 6 PD 1 Kidney 3
6 50/M 13 Kappa 11 HD 1 Kidney 2
7 67/F 17 Lambda 0.25 HD 2 Kidney 2
8 55/F 14 Lambda 4 HD 2 Kidney 1
9 56/M 5 Lambda 1 HD 2 Heart 3 
10 55/F 8 Kappa 5 HD 2 Kidney 2
11 50/F 10 Kappa 32 PD 1 Kidney 1
12 51/M 19 Lambda 17 HD 2 Kidney 5 
13 47/F 5 Kappa 3 HD 1 Heart 3 
14 64/F 21 Kappa 14 HD 2 Kidney 1
15 40/M 9 Lambda 0.25 HD 2 Kidney 2
Abbreviations: SWOG, Southwestern Oncology Group; HD, hemodialysis; PD, peritoneal dialysis.
a Disease duration is defined from time of tissue diagnosis of amyloidosis
b SWOG Performance Status scale: 0  asymptomatic; 1  symptomatic, fully ambulatory; 2  symptomatic, in bed 50% of day; 3  symptomatic, in bed 50%
of day; 4  bedridden.
c Affected organs include kidney, heart, gastrointestinal tract/liver, nervous system, endocrinologic system, and soft tissue
Analysis a result of respiratory failure 13 days after stem cell
infusion. Mucositis occurred in 11 of the ESRD patients.Response rates, complication rates, and survival of the
Median mucositis grade in the ESRD group was 2 com-15 patients with ESRD were compared with the 180
pared with a median grade of 1 in the non-ESRD patientspatients without ESRD treated during the same period.
(P  0.09) and the proportion of patients with grade 3Comparisons were performed using the Wilcoxon test
or 4 mucositis was greater in ESRD patients (43% vs.for continuous variables and Fisher’s exact test for cate-
20%; P 0.05). Neutropenic fever occurred in 67% of thegorical variables. Survival curves were generated using
ESRD patients. Three patients had culture-positive bac-the Kaplan-Meier technique and compared using the
teremia, one patient had pneumonia, and one patient hadlog-rank test. All analyses used a two-tailed significance
a mucocutaneous herpes simplex virus (HSV) infection.value of 0.05 and were performed with NCSS 2001 soft-
Red blood cell transfusion requirements were greater inware (NCSS.com, Kaysville, UT, USA).
ESRD patients (median, 4 units; range, 1 to 24 units) com-
pared with non-ESRD patients (median, 2 units; range,
RESULTS 0 to 35 units; P 0.04). Similarly, the platelet transfusion
Patients requirement for the ESRD patients (median, 10 units;
range, 0 to 48 units) was greater than that for the non-Baseline characteristics of the patients with AL amy-
ESRD patients (median, 4 units; range, 0 to 93 units;loidosis-associated ESRD treated with HDM/SCT are
P  0.03). Median number of days hospitalized, days toshown in Table 1. The median age of the patients was
neutrophil engraftment, and days to platelet engraftment51 years, 53% were male, and 60% had a lambda mono-
did not differ significantly between the ESRD and non-clonal protein. The median duration of dialysis-depen-
ESRD patients.dence prior to treatment was 7 months and the median
time from diagnosis of amyloidosis to treatment was 13
Response to treatment and survivalmonths. Five patients received peritoneal dialysis and
Treatment outcomes for the ESRD patients are shownthe remainder received hemodialysis. The majority of pa-
in Table 4. A hematologic complete response was evidenttients had extrarenal amyloid involvement and five pa-
at 12 months in eight of the 11 evaluable patients fortients had symptomatic cardiac disease.
an overall hematologic complete response rate of 53%.
Treatment-related toxicity Performance status was either unchanged or improved
following treatment in all surviving patients. With follow-Treatment related toxicities for the ESRD patients
up through February 2002, the median survival for theare shown in Tables 2 and 3. Two patients died within
15 ESRD patients was 25 months after treatment. Com-30 days of beginning stem cell mobilization (patients 9
parison of survival between the ESRD patients and non-and 11). One death was due to a ventricular arrhythmia
1 day following stem cell infusion and the other death was ESRD patients is shown in Figure 1. There was not a
Casserly et al: High-dose melphalan in AL amyloidosis-associated ESRD1054
Table 2. Treatment toxicities and blood product requirements in the end-stage renal disease (ESRD) patients
Red blood cell Platelet
Melphalan Mucositis Neutropenic Gastrointestinal Hospital transfusions transfusions
Patient mg/m2 grade 1 to 4 fever Infection bleed days units packs
1 100 0 0 2 0
2 100 4  Herpes simplex mucositis 4 6 10
3 100 0 2 1 0
4a 100  2 3  2 2 13
5a 100  2 1  1 4 7
6 200 2  8 3 2
7 140 2  Bacteremia 6 5 4
8 200 4  Bacteremia, multiple infections  49 24 48
9b 140 NAc 1 NAc NAc
10 200 4  Bacteremia 6 4 18
11b 140 0 1 4 10
12 140 3  10 13 16
13 200 1 7 3 12
14 70 1  Pneumonia 0 11 11
15 200 2  5 8 9
a Patients 4 and 5 received two courses of treatment with melphalan at 100 mg/m2 in a tandem fashion within 12 months
b Peritreatment death: Patient 9 died on Day 1 due to ventricular arrhythmia; Patient 11 died on Day 13 due to respiratory failure
c NA, not applicable because patient died 1 day following stem cell infusion
Table 3. Treatment-related toxicities in end-stage renal disease transplantation and have well-functioning allografts at
(ESRD) and non-ESRD patients
5.3 and 5.4 years after stem cell transplantation. One
ESRDa Non-ESRD patient underwent successful cadaveric renal transplan-
Complication N  14 N  180 P value tation and has a functioning allograft 6 years after treat-
Red blood cell transfusion units 4 (1–24) 2 (0–35) 0.04 ment. Two other patients with hematologic complete
Platelet transfusion units 10 (0–48) 4 (0–93) 0.03
response are on waiting lists for cadaveric renal trans-Hospitalization days 4.5 (0–49) 7 (0–60) 0.17
Mucositis grade 2 (0–4) 1 (0–4) 0.09 plantation. In the two patients who survived more than
Mucositis grade 3 or 4 % 43 20 0.05 3 months but less than 1 year (i.e, patients not evaluable
Neutrophil engraftment days 11.5 (9–19) 10 (7–17) 0.09
at 12 months), persistent plasma cell disease was presentPlatelet engraftment days 17 (10–39) 14 (0–65) 0.14
Gastrointestinal bleed % 7 13 0.7 in one (patient 3) and a hematologic complete response
was evident in the other (patient 12) at the 3-montha ESRD patient 11 was excluded from analysis because of death on day 1. For
those patients who received two courses of treatment only complications from follow-up evaluation.
the first treatment course were analyzed. Continuous variables are presented as
medians with range.
DISCUSSION
This is the first report detailing the outcomes of dose-
statistically significant difference in survival between the intensive melphalan and autologous blood stem cell trans-
two groups. plantation in patients with AL amyloidosis-associated
The small size of the ESRD cohort precludes formal ESRD. Eight of the 15 patients (53%) had a complete
comparisons of outcomes between patients with hemato- hematologic response evident 12 months after treatment,
logic complete response and those without. However, it and six of these eight patients (75%) are alive at a median
is noteworthy that none of the three patients with per- follow-up of 4.5 years. The median survival of 25 months
sistence of the plasma cell dyscrasia at 12 months sur- for all ESRD patients exceeds the median survival re-
vived beyond 2.2 years while six of the eight patients ported in other series for all AL amyloidosis patients
with a hematologic complete response are still alive at treated with oral melphalan and prednisone [3, 5]. Three
a median follow-up of 4.5 years (range, 1.4 to 6.1 years). of the patients have received renal allografts and two
Four of these six patients received melphalan at a dose patients have been placed by their referring centers on
of 200 mg/m2. Among the patients who did not achieve waiting lists for cadaveric renal transplantation.
a hematologic complete response, one (patient 5) died Median survival in those eight patients with a hemato-
from an anaphylactic reaction to cyclosporine, one (pa- logic complete response at 12 months was 4.5 years com-
tient 7) died from a hemorrhagic cerebral infarct that pared with survival of 13 to 26 months in the three sub-
was unrelated to amyloidosis, and one (patient 13) died jects who did not achieve a hematologic complete response.
from a cardiac arrhythmia that was related to cardiac This association between hematologic outcome and sur-
amyloidosis. Two patients with hematologic complete vival is evident in the full cohort of patients treated at
this institution as well [10]. Of note, the hematologic com-response have undergone successful living-related renal
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Table 4. Treatment outcomes in the end-stage renal disease (ESRD) patients
Hematologic Death
response at Survival Renal attributed to
Patient 12 monthsa status/follow-up transplantation Cause of death amyloid
1 Non-CR Dead/26 months Arrhythmia Yes
2 CR Alive/73 months Yes
3 Not available Dead/9 months Sudden death Yes
4 CR Alive/65 months Yes
5 Non-CR Dead/13 months Anaphylaxis to cyclosporine No
6 CR Alive/64 months Yes
7 CR Dead/58 months Hemorrhagic CVA No
8 Non-CR Dead/17 months Pulmonary/renal failure and infection Yes
9 Not available Dead/0 months Arrythmia Yes
10 CR Alive/50 months Waiting list
11 Not available Dead/0.4 months Pulmonary failure No
12 Not available Dead/11 months Sudden death Yes
13 CR Dead/17 months Arrhythmia Yes
14 CR Alive/37 months
15 CR Alive/34 months Waiting list
Abbreviations are: CR, hematologic complete response; Non-CR, hematologic noncomplete response; CVA, cerebrovascular accident.
a Classified as “Not available” if death occurred before 1 year
Fig. 1. Survival from time of treatment of end-
stage renal disease (ESRD) patients compared
with non-ESRD patients (P 0.1 by log-rank
test).
plete response rate in the ESRD patients is at least as vere in patients with AL amyloidosis because of underly-
ing organ dysfunction. Peritransplant mortality rates ingood as that seen in the full cohort (53% vs. 41%) [10].
Although the small number of ESRD patients studied AL amyloidosis patients range from 14% to 44% at dif-
ferent institutions [8, 9, 13, 15, 16]. In this series, thelimits the power for comparisons with the non-ESRD
group, a trend toward inferior long-term survival in the peritransplant mortality of 13% is no different than that
of the full cohort of 195 patients (14%). Thus, ESRD isESRD patients is apparent, particularly between the first
and second years following treatment (Fig. 1). Such a not a predictor of increased treatment-related mortality.
However, the ESRD patients did have more severe mu-finding is not unexpected given the negative impact of
ESRD on survival in the general population. cositis and an increased requirement for red cell and
platelet transfusion support. In previous studies fromHigh-dose myelosuppressive chemotherapy is associ-
ated with significant toxicity that can be particularly se- this institution, symptomatic cardiac disease was found to
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be the single most powerful predictor of poor treatment SCT appears to be the most effective treatment for AL
amyloidosis. Our findings demonstrate that such treatmentoutcome [10]. It is noteworthy that all five of the 15 pa-
tients in this series with cardiac disease in addition to is tolerable and effective in selected patients with ESRD.
We conclude that aggressive treatment with HDM/SCTESRD died of cardiac-related complications, although
only one of these deaths occurred during the peritrans- should be considered for patients with AL amyloidosis-
plant period. associated ESRD and it would be unjustified to exclude
One might have predicted that certain treatment com- them a priori from such treatment. However, strategies
plications such as bleeding and infection would be par- to limit mucositis and minimize infectious complications
ticularly frequent or severe in dialysis patients receiving should be sought to moderate the toxicity of treatment.
high-dose chemotherapy. Gastrointestinal bleeding has
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